Mankind Pharma Share Price

    NSE
    2491.1
    +59.40 (2.44%)
    MANKIND • 09 Jul, 2025 | 10:31 AM
    BUY
    The current prices are delayed, login or Open Demat Account for live prices.

    Mankind Pharma Stock Performance

    1W Return3.98
    1Y Return17.93
    Today's Low2417.6
    Prev. Close2,431.70
    Mkt Cap (Cr.)1,00,363.25
    1M Return5.21
    3Y Return0.00
    52-Week High3054.8
    Open2,419.50
    PE Ratio53.24
    6M Return-12.32
    Today's High2480
    52-Week Low1901.05
    Face Value1

    Mankind Pharma Company background

    Founded in: 1991

    Mankind Pharma Limited was established on July 3, 1991, as a private limited company under the name Mankind Pharma Private Limited, registered with the Registrar of Companies in Delhi and Haryana. In 2005, the company underwent a significant transformation, converting into a public limited company. Subsequently, the name was changed to Mankind Pharma Limited, and a fresh certificate of incorporation was issued on April 13, 2006. Over the years, Mankind Pharma has emerged as one of India’s leading pharmaceutical companies, specializing in the development, manufacturing, and marketing of pharmaceutical formulations and consumer healthcare products.

    The company operates across various acute and chronic therapeutic segments, offering solutions in anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins, minerals, nutrients, and respiratory treatments. Its ability to cater to a broad spectrum of health concerns has solidified its position in the Indian pharmaceutical market.

    Mankind Pharma made a strategic entry into the chronic pharmaceutical segment in 2004 with the launch of notable products such as Amlokind tablets and Glimestar tablets. These products marked the company’s diversification from acute therapies into chronic care, catering to long-term medical conditions such as hypertension and diabetes. This move not only expanded the company’s portfolio but also established its reputation as a comprehensive healthcare provider.

    To support its growing operations, Mankind Pharma set up its first manufacturing facility at Paonta Sahib, Himachal Pradesh, in 2005. This facility became a cornerstone for the company’s production capabilities, enabling it to meet increasing market demand.

    In 2007, Mankind Pharma ventured into the consumer healthcare segment with the launch of its flagship Manforce brand. This brand quickly became synonymous with high-quality condoms and opened avenues for the company to explore other consumer healthcare products. Over the years, the company introduced several innovative and differentiated products in this segment, including Pregnancy Detection Kits (Preganews), emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations.

    The success of the Manforce brand and other consumer healthcare products not only strengthened Mankind Pharma’s market presence but also demonstrated its ability to address the evolving needs of Indian consumers.

    Mankind Pharma consistently identified and entered new business segments to sustain growth. The company expanded into the ophthalmic pharmaceutical segment with the launch of Lubistar Eye Drops and Tobastar Eye Drops. Recognizing the potential of the animal healthcare market, the company introduced products such as Bandykind and Ceftiforce, catering to veterinary needs.

    In 2010, the company launched the popular Preganews brand, a pregnancy detection kit that quickly became a household name in India. This product further solidified Mankind Pharma’s leadership in the consumer healthcare sector.

    Mankind Pharma has always prioritized research and development to stay ahead in the competitive pharmaceutical industry. In 2012, the company established its first R&D center at IMT Manesar, Haryana, marking a significant milestone in its journey. This facility has been instrumental in the development of innovative products and formulations, enabling the company to maintain a strong pipeline of pharmaceutical and consumer healthcare products.

    In 2014, Mankind Pharma acquired Shree Jee Laboratory Private Limited, along with its API (Active Pharmaceutical Ingredient) manufacturing site at Behror, Rajasthan. This acquisition bolstered the company’s production capabilities and ensured a steady supply of high-quality APIs for its formulations.

    To expand its global footprint, Mankind Pharma established subsidiaries such as Lifestar Pharma LLC in the US and Mankind Pharma Pte. Limited in Singapore in 2015. These subsidiaries facilitated the company’s entry into international markets, allowing it to cater to a global audience.

    In 2021, the company further expanded its global operations by incorporating Mankind Pharma FZ-LLC in Dubai, UAE, a move that underscored its ambition to strengthen its presence in the Middle East.

    Mankind Pharma continued to innovate and expand its product portfolio by entering specialty therapeutic areas. In 2019, the company launched Dydroboon tablets for female infertility, marking its entry into the fertility segment.

    In subsequent years, it introduced a range of specialty products, including Cilaheart and Statpure tablets for cardiovascular diseases, Zukanorm tablets for diabetes, and Mlife tablets for respiratory diseases. The company also ventured into the neuro/CNS pharmaceutical segment with the launch of Trugaba-NT tablets and Prebris-MNT tablets.

    Recognizing the growing demand for advanced medical treatments, Mankind Pharma entered the oncology segment in 2022 with the launch of Pacliall injection, a chemotherapy drug. The company also ventured into the transplant segment, introducing products such as Pangraf capsules and Mycept tablets.

    These strategic launches highlight Mankind Pharma’s commitment to addressing complex medical conditions and providing innovative solutions to patients.

    As of March 31, 2022, Mankind Pharma operated 23 manufacturing facilities across India, employing 2,181 manufacturing personnel. These facilities have a combined installed capacity of 40.77 billion units, encompassing a wide range of dosage forms such as tablets, capsules, syrups, vials, ampoules, soft and hard gels, eye drops, creams, and over-the-counter products.

    The company’s state-of-the-art manufacturing infrastructure ensures high-quality production standards and enables it to meet the diverse needs of its customers.

    Mankind Pharma has consistently demonstrated strong financial performance, attracting the attention of investors and analysts alike. The company’s decision to raise capital through a public offering of 40,058,844 equity shares via an Offer for Sale reflects its confidence in future growth prospects.

    The Mankind Pharma share price is a key indicator of the company’s market performance and investor sentiment. As the company continues to expand its operations and introduce innovative products, the share price is expected to remain a focus of attention for market participants.

    With a robust product portfolio, a strong presence in both pharmaceutical and consumer healthcare segments, and a commitment to innovation, Mankind Pharma is well-positioned for sustained growth. Its entry into high-potential therapeutic areas such as oncology and transplant medicine, coupled with its global expansion initiatives, underscores its ambition to become a leading player in the global pharmaceutical industry.

    The Mankind Pharma share price will likely reflect the company’s ongoing efforts to enhance shareholder value, driven by its diversified business model and strategic vision.

    As of 09 Jul, 2025, Mankind Pharma share price is ₹2479.5. The stock opened at ₹2419.5 and had closed at ₹2431.7 the previous day. During today’s trading session, Mankind Pharma share price moved between ₹2,417.60 and ₹2,480.00, with an average price for the day of ₹2448.80. Over the last 52 weeks, the stock has recorded a low of ₹1,901.05 and a high of ₹3,054.80. In terms of performance, Mankind Pharma share price has declined by 13.9% over the past six months and has increased by 15.66% over the last year.

    Read More
    View details of Market Depth

    Mankind Pharma Fundamental

    Market Cap (in crs)

    1,00,363.25

    Face Value

    1

    Turnover (in lacs)

    2,679.30

    Key Metrics

    Qtr Change %
    30.43% Gain from 52W Low
    5.6
    Dividend yield 1yr %
    0

    Mankind Pharma Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Mankind Pharma Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    3079.37 Cr
    3230 Cr
    3076.51 Cr
    2893.42 Cr
    2441.1 Cr
    Mankind Pharma Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    12744.23 Cr
    10615.63 Cr
    8878 Cr
    7977.58 Cr
    6385.38 Cr
    5975.65 Cr
    Mankind Pharma Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    426.67 Cr
    381.08 Cr
    656.31 Cr
    539.16 Cr
    474.18 Cr
    Mankind Pharma Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    1998.88 Cr
    1926.56 Cr
    1297.25 Cr
    1438.51 Cr
    1281.36 Cr
    1044.61 Cr

    Mankind Pharma Result Highlights

    • Mankind Pharma Ltd reported a 23.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 20.6%.

    • Its expenses for the quarter were down by 30.2% QoQ and up 13.8% YoY.

    • The net profit increased 23.9% QoQ and increased 62.3% YoY.

    • The earnings per share (EPS) of Mankind Pharma Ltd stood at 11.7 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Mankind Pharma

    Promoter
    72.7%
    Foreign Institutions
    12.9%
    Mutual Funds
    7.7%
    Domestic Institutions
    11.5%
    Public
    2.9%
    Promoter
    72.7%
    Foreign Institutions
    13.3%
    Mutual Funds
    7.8%
    Domestic Institutions
    11.1%
    Public
    2.9%
    Promoter
    74.9%
    Foreign Institutions
    12.4%
    Mutual Funds
    7%
    Domestic Institutions
    9.9%
    Public
    2.9%
    Promoter
    74.9%
    Foreign Institutions
    11.6%
    Mutual Funds
    7.4%
    Domestic Institutions
    9.9%
    Public
    3.6%
    Promoter
    74.9%
    Foreign Institutions
    9.9%
    Mutual Funds
    8.6%
    Domestic Institutions
    11.1%
    Public
    4.1%
    Promoter
    76.5%
    Foreign Institutions
    6.7%
    Mutual Funds
    7.6%
    Domestic Institutions
    9.8%
    Public
    7%

    Mankind Pharma Technical Analysis

    Moving Averages Analysis
    2491.1
    Current Price
    Bullish Moving Averages
    14
    Bearish Moving Averages
    2
    5Day EMA
    2,401.80
    10Day EMA
    2,377.40
    12Day EMA
    2,372.90
    20Day EMA
    2,369.90
    26Day EMA
    2,374.00
    50Day EMA
    2,393.60
    100Day EMA
    2,422.80
    200Day EMA
    2,418.70
    5Day SMA
    2,405.60
    10Day SMA
    2,358.00
    20Day SMA
    2,351.70
    30Day SMA
    2,366.80
    50Day SMA
    2,412.30
    100Day SMA
    2,395.10
    150Day SMA
    2,488.70
    200Day SMA
    2,519.60
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    141379 Rs
    241498 Rs
    Week Rs
    295168 Rs
    1019277 Rs
    Month Rs
    300275 Rs
    584023 Rs
    2,427.63
    Pivot
    Resistance
    First Resistance
    2,447.17
    Second Resistance
    2,462.63
    Third Resistance
    2,482.17
    Support
    First Support
    2,412.17
    Second support
    2,392.63
    Third Support
    2,377.17
    Relative Strength Index
    57.74
    Money Flow Index
    57.89
    MACD
    -1.16
    MACD Signal
    -18.58
    Average True Range
    57.70
    Average Directional Index
    14.45
    Rate of Change (21)
    3.18
    Rate of Change (125)
    -15.70
    Name
    Holding Percent
    SBI LARGE & MIDCAP FUND
    1.58
    AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL F
    1.29
    GOVERNMENT PENSION FUND GLOBAL
    1.52
    SBI Life Insurance Co. Ltd.
    1.05
    NPS TRUST- A/C SBI PENSION FUND PVT LTD APY FUND S
    1.02

    Mankind Pharma Latest News

    04 JUL 2025 | Friday

    Mankind Pharma Ltd - 543904 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    04 JUL 2025 | Friday

    Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    03 JUL 2025 | Thursday

    Mankind Pharma Ltd - 543904 - Intimation Of The Date Of 34Th Annual General Meeting (AGM) Of The Company

    View More

    Mankind Pharma Share Price FAQs

    Mankind Pharma share price is ₹2491.1 in NSE and ₹2494 in BSE as on 9/7/2025.

    Mankind Pharma share price in the past 1-year return was 17.93. The Mankind Pharma share hit a 1-year low of Rs. 1901.05 and a 1-year high of Rs. 3054.8.

    The market cap of Mankind Pharma is Rs. 100363.25 Cr. as of 9/7/2025.

    The PE ratios of Mankind Pharma is 53.24 as of 9/7/2025.

    The PB ratios of Mankind Pharma is 6.85 as of 9/7/2025

    The Mutual Fund Shareholding in Mankind Pharma was 7.67% at the end of 9/7/2025.

    You can easily buy Mankind Pharma shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Mankind Pharma share price is ₹3054.8 and ₹1901.05 as of 9/7/2025.

    Please be aware that Mankind Pharma stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    66.27
    +0.01 (+0.02%)
    138.04
    -0.16 (-0.12%)
    691.80
    -1.40 (-0.20%)
    2,594.40
    +3.10 (+0.12%)
    165.41
    -1.07 (-0.64%)
    387.40
    +0.90 (+0.23%)
    159.27
    -2.70 (-1.67%)
    264.35
    +0.85 (+0.32%)
    421.55
    -0.45 (-0.11%)
    400.50
    -0.35 (-0.09%)
    Top Gainers
    2,524.30
    +39.70 (+1.60%)
    941.70
    +14.05 (+1.51%)
    2,424.40
    +31.70 (+1.32%)
    5,498.00
    +58.00 (+1.07%)
    331.80
    +2.95 (+0.90%)
    Top Losers
    159.15
    -2.82 (-1.74%)
    1,680.00
    -28.10 (-1.65%)
    680.00
    -5.60 (-0.82%)
    1,430.80
    -11.20 (-0.78%)
    267.75
    -1.90 (-0.70%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -